Johnson & Johnson Covid-19 vaccine study paused due to illness

Johnson & Johnson Covid-19 vaccine study paused due to illness

Johnson & Johnson vaccine study paused

Johnson & Johnson has paused enrolment in its COVID-19-vaccine trial because of “an unexplained illness in a study participant”. It’s not known whether the person received the vaccine or a placebo. The phase III study aims to look for proof of efficacy and safety in 60,000 people. Pauses are par for the course in such large trials, say scientists. The trial of a vaccine candidate from the University of Oxford, UK, and pharmaceutical company AstraZeneca has been on hold in the United States since 8 September, although it has restarted in the United Kingdom and elsewhere.

STAT | 7 min read